Chester County News and Community Website
WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) received a revised Nov. 10 regulatory goal date for its preservative-free ketamine application after the U.S. Food and Drug Administration reclassified a …
NRx Gets Earlier FDA Goal Date for Ketamine Application Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. said its HOPE Therapeutics subsidiary will become the first interventional psychiatry network to deploy Zeta Surgical’s newly FDA-cleared robotic transcranial magnetic stimulation system, expanding …
HOPE Adds Robotic TMS System Ahead of SPARC Trial Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) moved closer to a potential 2026 launch of preservative-free ketamine after the Food and Drug Administration found no major deficiencies involving the …
NRx Advances Ketamine Bid After FDA Review Clears Drug Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) said its subsidiary, HOPE Therapeutics, has begun treating patients using an artificial intelligence-guided transcranial magnetic stimulation system, a move the company says …
NRx Subsidiary Begins AI-Guided TMS Treatments in Florida Clinics Read More WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) said the U.S. Food and Drug Administration has authorized an Expanded Access Protocol for its investigational depression treatment NRX-101, potentially allowing certain patients …
FDA Clears Expanded Access Path for NRx Depression Therapy Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) moved closer to potential commercialization of its preservative-free ketamine product in the first quarter as the company scaled manufacturing, advanced multiple FDA …
NRx Pushes Toward Ketamine Launch Amid FDA Review Read More WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) received U.S. Food and Drug Administration clearance to begin a late-stage clinical trial evaluating whether its investigational NRX-101 therapy can improve outcomes for …
NRx Advances Depression Drug Study Targeting Military Use Read More WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) has placed its first commercial manufacturing order for a preservative-free ketamine product ahead of a potential U.S. approval expected under the Generic Drug …
NRx Begins Ketamine Production Ahead of FDA Decision Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently received a Discipline Review Letter from the U.S. Food and Drug Administration identifying only minor administrative changes for its ketamine application …
NRx Reports FDA Feedback, Progress on Ketamine Application Read More WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) said it supports an executive order signed April 18, 2026, directing federal agencies to accelerate research and regulatory pathways for treatments targeting serious …
NRx Pharmaceuticals Responds to Executive Order on Mental Health Treatments Read More